# US 2023/0390399 A1 · Injectable preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390399 A1
- Document ID: US20230390399A1
- Status: Published application
- Kind: A1
- Application number: 18/148,860
- Filed: 2022-12-30
- Published: 2023-12-07
- Earliest claimed: 2012-04-23
- Assignees: Otsuka Pharmaceutical Co., Ltd.
- Applicants: Otsuka Pharmaceutical Co., Ltd.
- Inventors: Daiki KANEKO; Takakuni MATSUDA; Yusuke HOSHIKA
- Web page: https://patentgrep.com/patent/US20230390399A1

## CPC

- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s−1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s−1, as measured.

## Claims

### Claim at position 1

1-37. (canceled)

### Claim 38

A gel composition comprising:
aripiprazole or a salt thereof,
water, and
polyvinylpyrrolidone with a K value ranging from 12 to 30,
wherein a concentration of the polyvinylpyrrolidone ranges from 0.1 mg/mL to 100 mg/mL, and the aripiprazole or a salt thereof has a mean primary particle diameter ranging from 0.5 μm to 30 μm, and a concentration of the aripiprazole or a salt thereof ranges from 200 mg/mL to 600 mg/mL, which is calculated as an anhydrate.

### Claim 39 (depends on 38)

The gel composition according to claim 38, wherein K value of the polyvinylpyrrolidone ranges from 12 to 20.

### Claim 40 (depends on 39)

The gel composition according to claim 39, wherein K value of the polyvinylpyrrolidone is 17.

### Claim 41 (depends on 38)

The gel composition according to claim 38, further comprising polyethylene glycol.

### Claim 42 (depends on 38)

The gel composition according to claim 38, further comprising polyethylene glycol and carboxymethyl cellulose or a salt thereof.

### Claim 43 (depends on 42)

The gel composition according to claim 42, wherein a concentration of the polyethylene glycol ranges from 0.1 mg/mL to 100 mg/mL, and a concentration of the carboxymethyl cellulose or a salt thereof ranges from 0.5 mg/mL to 50 mg/mL.

### Claim 44 (depends on 43)

The gel composition according to claim 43, wherein the concentration of the polyvinylpyrrolidone ranges from 2 mg/mL to 20 mg/mL, the concentration of the polyethylene glycol ranges from 0.1 mg/mL to 50 mg/mL, and the concentration of the carboxymethyl cellulose or a salt thereof ranges from 2 mg/mL to 20 mg/mL.

### Claim 44 (depends on 42)

The gel composition according to claim 42, wherein the polyethylene glycol is polyethylene glycol 400, and the concentration of the polyethylene glycol ranges from 0.5 mg/mL to 5 mg/mL.

### Claim 45 (depends on 42)

The gel composition according to claim 42, wherein the polyethylene glycol is polyethylene glycol 4000, and the concentration of the polyethylene glycol ranges from 0.1 mg/mL to 40 mg/mL.

### Claim 46 (depends on 38)

The gel composition according to claim 38, wherein the concentration of the aripiprazole or salt thereof ranges from 250 mg/mL to 450 mg/mL.

### Claim 47 (depends on 38)

The gel composition according to claim 38, wherein the aripiprazole or a salt thereof is a monohydrate of aripiprazole or a salt thereof.

### Claim 48 (depends on 38)

The gel composition according to claim 38, wherein the mean primary particle diameter ranges from 1 μm to 10 μm.

### Claim 49 (depends on 48)

The gel composition according to claim 48, wherein the mean primary particle diameter ranges from 2 μm to 7 μm.

### Claim 50 (depends on 38)

The gel composition according to claim 38, wherein the aripiprazole or a salt thereof has a mean secondary particle diameter up to but not exceeding three times the mean primary particle diameter thereof.

### Claim 51 (depends on 38)

The gel composition according to claim 38, wherein the composition has a viscosity of 40 Pa·s or more in at least one point in a shear rate ranging from 0.01 s−1 to 0.02 s−1, and a viscosity of 0.2 Pa·s or less in at least one point in a shear rate ranging from 900 s−1 to 1,000 s−1, as measured by a rheometer at 25° C.

### Claim 52 (depends on 38)

The gel composition according to claim 38, wherein the composition is disposed within a prefilled syringe in gel form for storage and forms a sol when subjected to an impact.

### Claim 53 (depends on 38)

The gel composition according to claim 38, wherein the composition is administered once every two to three months.

### Claim 54 (depends on 38)

A method for treating schizophrenia, bipolar disorder, or depression, the method comprising administering the gel composition according to claim 38 to a patient in need thereof.

### Claim 55

A method for treating schizophrenia, bipolar disorder, or depression in a subject in need thereof, comprising administering a pharmaceutical composition,
wherein the method comprising preparing the pharmaceutical composition comprising;
aripiprazole or a salt thereof,
water, and
polyvinylpyrrolidone,
wherein a K value of the polyvinylpyrrolidone ranges from 12 to 30, a concentration of the polyvinylpyrrolidone ranges from 0.1 mg/mL to 100 mg/mL, the aripiprazole or a salt thereof has a mean primary particle diameter of ranging from 0.5 μm to 30 μm, and a concentration of the aripiprazole or a salt thereof ranges from 200 mg/mL to 600 mg/mL, which is calculated as an anhydrate.

### Claim 56 (depends on 55)

The method according to claim 55, wherein the pharmaceutical composition is an injectable preparation in a gel form for storage and forms a sol when subjected to an impact.

### Claim 57 (depends on 56)

The method according to claim 56, wherein the pharmaceutical composition is an injectable preparation in a gel form for storage and is administered to a patient in need thereof in a sol form.

### Claim 58 (depends on 56)

The method according to claim 56, wherein the pharmaceutical composition is administered once every two months.

### Claim 59 (depends on 57)

The method according to claim 57, wherein the pharmaceutical composition is administered once every two months.

### Claim 60 (depends on 58)

The method according to claim 58, wherein the pharmaceutical composition is administered intramuscularly.

### Claim 61 (depends on 59)

The method according to claim 59, wherein the pharmaceutical composition is administered intramuscularly.

### Claim 62

A pharmaceutical composition comprising:
aripiprazole or a salt thereof,
water,
polyvinylpyrrolidone with a K value ranging from 12 to 20,
carboxymethyl cellulose or a salt thereof with a concentration ranging from 2 mg/mL to 20 mg/mL, and
polyethylene glycol with a concentration ranging from 0.1 mg/mL to 50 mg/mL,
wherein a concentration of the polyvinylpyrrolidone ranges from 0.1 mg/mL to 50 mg/mL, the aripiprazole or a salt thereof has a mean primary particle diameter ranging from 1 μm to 10 μm and a concentration of the aripiprazole or a salt thereof ranges from 250 mg/mL to 450 mg/mL, which is calculated as an anhydrate, and
wherein the pharmaceutical composition is disposed within a container in gel form for storage and changes to a sol when subjected to an impact, and the pharmaceutical composition is administered once every two months.

### Claim 63 (depends on 62)

The pharmaceutical composition according to claim 62, wherein K value of polyvinylpyrrolidone is 17.

### Claim 64 (depends on 62)

The pharmaceutical composition according to claim 62, wherein the polyethylene glycol is polyethylene glycol 400, and the polyethylene glycol 400, and a concentration of the polyethylene glycol ranges from 0.5 mg/mL to 5 mg/mL.

### Claim 65 (depends on 62)

The pharmaceutical composition according to claim 62, wherein the polyethylene glycol is polyethylene glycol 4000, and the polyethylene glycol 4000, and a concentration of the polyethylene glycol ranges from 0.1 mg/mL to 40 mg/mL.

### Claim 66

A method for treating schizophrenia, bipolar disorder, or depression in a subject in need thereof, comprising administering a pharmaceutical composition,
wherein the pharmaceutical composition comprises;
aripiprazole or a salt thereof,
water,
polyvinylpyrrolidone with a K value ranging from 12 to 20,
carboxymethyl cellulose or a salt thereof with a concentration ranging from 2 mg/mL to 20 mg/mL, and
polyethylene glycol with a concentration ranging from 0.1 mg/mL to 50 mg/mL, wherein a concentration of the polyvinylpyrrolidone ranges from 0.1 mg/mL to 50 mg/mL, the aripiprazole or a salt thereof has a mean primary particle diameter ranging from 1 μm to 10 μm, and a concentration of the aripiprazole or a salt thereof ranges from 250 mg/mL to 450 mg/mL, which is calculated as an anhydrate, and
wherein the pharmaceutical composition changes to a sol when subjected to an impact, and the pharmaceutical composition is administered once every two months.

### Claim 67 (depends on 66)

The method according to claim 66, wherein the pharmaceutical composition is administered intramuscularly.

### Claim 68

A gel composition comprising:
aripiprazole monohydrate or a salt thereof,
water,
polyvinylpyrrolidone with a K value ranging from 12 to 20,
carboxymethyl cellulose or a salt thereof with a concentration ranging from 2 mg/mL to 20 mg/mL, and
polyethylene glycol with a concentration ranging from 0.1 mg/mL to 50 mg/mL,
wherein a concentration of the polyvinylpyrrolidone ranges from 0.1 mg/mL to 50 mg/mL, the aripiprazole monohydrate or a salt thereof has a mean primary particle diameter ranging from 0.5 μm to 30 μm, and a concentration of the aripiprazole monohydrate or a salt thereof ranges from 208 mg/mL to 416 mg/mL.

### Claim 69 (depends on 68)

The gel composition according to claim 68, wherein K value of the polyvinylpyrrolidone is 17.

### Claim 70 (depends on 68)

The gel composition according to claim 68, wherein the polyethylene glycol is polyethylene glycol 400, and the concentration of the polyethylene glycol ranges from 0.5 mg/mL to 5 mg/mL.

### Claim 71 (depends on 68)

The gel composition according to claim 68, wherein the polyethylene glycol is polyethylene glycol 4000, and the concentration of the polyethylene glycol ranges from 0.1 mg/mL to 40 mg/mL.

### Claim 72

A method for treating schizophrenia, bipolar disorder, or depression in a subject in need thereof, comprising administering a pharmaceutical composition,
wherein the pharmaceutical composition comprises:
aripiprazole monohydrate or a salt thereof,
water,
polyvinylpyrrolidone with a K value ranging from 12 to 20,
carboxymethyl cellulose or a salt thereof with a concentration of the carboxymethyl cellulose or a salt thereof ranges from 2 mg/mL to 20 mg/mL, and
polyethylene glycol with a concentration of the polyethylene glycol ranges from 0.1 mg/mL to 50 mg/mL,
wherein a concentration of the polyvinylpyrrolidone ranges from 0.1 mg/mL to 50 mg/mL, the aripiprazole monohydrate or a salt thereof has a mean primary particle diameter ranging from 0.5 μm to 30 μm, and a concentration of the aripiprazole monohydrate or a salt thereof ranges from 208 mg/mL to 416 mg/mL.

### Claim 73 (depends on 72)

The method according to claim 72, wherein the pharmaceutical composition is an injectable preparation in a gel form for storage and forms a sol when subjected to an impact, and the composition is administered once every two months.

### Claim 74 (depends on 72)

The method according to claim 72, wherein the pharmaceutical composition is administered intramuscularly.
